scholarly journals Assessment of insulin sensitivity and insulin secretion from the oral glucose tolerance test in nonobese Japanese type 2 diabetic patients: comparison with minimal-model approach

Diabetes Care ◽  
2000 ◽  
Vol 23 (9) ◽  
pp. 1439-1440 ◽  
Author(s):  
A. Taniguchi ◽  
S. Nagasaka ◽  
M. Fukushima ◽  
M. Sakai ◽  
I. Nagata ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Diabetic Patients ◽  
Oral Glucose Tolerance ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic ◽  
Model Approach

scholarly journals Antidiabetic Effects of Add-OnGynostemma pentaphyllumExtract Therapy with Sulfonylureas in Type 2 Diabetic Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
V. T. T. Huyen ◽  
D. V. Phan ◽  
P. Thang ◽  
P. T. Ky ◽  
N. K. Hoa ◽  
...  
Keyword(s):  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Diabetic Patients ◽  
Oral Glucose Tolerance ◽  
Type 2 Diabetic Patients ◽  
Drug Naïve ◽  
Type 2 Diabetic ◽  
Antidiabetic Effects

Aims.To investigate the antidiabetic effect of the traditional Vietnamese herbGynostemma pentaphyllum(GP) together with sulfonylurea (SU) in 25 drug-naïve type 2 diabetic patients.Methods.After 4-week treatment with gliclazide (SU), 30 mg daily, all patients were randomly assigned into 2 groups to add on GP extract or placebo extract, 6 g daily, during eight weeks.Results.After 4-week SU treatment, fasting plasma glucose (FPG) and HbA1Cdecreased significantly (P<0.001). FPG was further reduced after add-on therapy with 2.9 ± 1.7 and 0.9 ± 0.6 mmol/L in the GP and placebo groups, respectively (P<0.001). Therapy with GP extract also reduced 30- and 120-minute oral glucose tolerance test postload values. HbA1Clevels decreased approximately 2% units in the GP group compared to 0.7% unit in the placebo group (P<0.001).Conclusion.GP extract in addition to SU offers an alternative to addition of other oral medication to treat type 2 diabetic patients.

scholarly journals Effect of eicosapentaenoic acid ethyl ester v. oleic acid-rich safflower oil on insulin resistance in type 2 diabetic model rats with hypertriacylglycerolaemi

2002 ◽  
Vol 87 (2) ◽  
pp. 157-162 ◽  
Author(s):  
Asako Minami ◽  
Noriko Ishimura ◽  
Sadaichi Sakamoto ◽  
Eiko Takishita ◽  
Kazuaki Mawatari ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Oleic Acid ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Abdominal Fat ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
Oletf Rats ◽  
Type 2 Diabetic

The purpose of the present study was to test whether hyperlipidaemia and insulin resistance in type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats can be improved by dietary supplementation with purified eicosapentaenoic acid (EPA) or oleic acid (OA). Male OLETF rats were fed powdered chow (510 g fat/kg) alone (n 8) or chow supplemented with 1·0 g EPA- (n 8) or OA- (n 8) rich oil/kg per d from 5 weeks until 30 weeks of age. An oral glucose tolerance test and hyperinsulinaemic euglycaemic clamp was performed at 25 and 30 weeks of age. EPA supplementation resulted in significantly (P<0.05) reduced plasma lipids, hepatic triacylglycerols, and abdominal fat deposits, and more efficient in vivo glucose disposal compared with OA supplementation and no supplementation. OA supplementation was associated with significantly increased insulin response to oral glucose compared with EPA supplementation and no supplementation. Inverse correlation was noted between glucose uptake and plasma triacylglycerol levels (r -0·86, P<0·001) and abdominal fat volume (r -0·80, P<0·001). The result of oral glucose tolerance test study showed that the rats fed EPA tended to improve glucose intolerance, although this was not statistically significant. Levels of plasma insulin at 60 min after glucose was significantly increased in rats fed OA compared with the other two groups. The results indicate that long-term feeding of EPA might be effective in preventing insulin resistance in diabetes-prone rats, at least in part, due to improving hypertriacylglycerolaemia.

scholarly journals Assessment of insulin secretion from the oral glucose tolerance test in white patients with type 2 diabetes

Diabetes Care ◽  
2000 ◽  
Vol 23 (9) ◽  
pp. 1440-1441 ◽  
Author(s):  
M. Stumvoll ◽  
A. Mitrakou ◽  
W. Pimenta ◽  
T. Jenssen ◽  
H. Yki-Jarvinen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Secretion ◽  
Glucose Tolerance ◽  
Oral Glucose Tolerance Test ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Oral Glucose Tolerance ◽  
White Patients

Conformance of the diagnostic criteria for diabetes mellitus estimated from the results of the oral glucose tolerance testsand glycated hemoglobin (HbA1c) level

2014 ◽  
Vol 60 (1) ◽  
pp. 36-38
Author(s):  
E A Shestakova
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Tolerance ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Diabetic Patients ◽  
Oral Glucose Tolerance ◽  
Study Population ◽  
Hba1c Measurement

The study population of 127 patients with type 2 diabetes mellitus (T2DM) risk factors underwent oral glucose tolerance test (OGTT) and HbA1c measurement for diagnostic reasons. HbA1c revealed less diabetic patients than OGTT (31% vs 43%). HbA1c >7% and OGTT were similar in confirming diabetes, but HbA1c <7% suggests the need for OGTT performance to validate the diagnosis.

scholarly journals Statins Are Associated With Increased Insulin Resistance and Secretion

2021 ◽  
Author(s):  
Fahim Abbasi ◽  
Cindy Lamendola ◽  
Chelsea S. Harris ◽  
Vander Harris ◽  
Ming-Shian Tsai ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Insulin Secretion ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Atherosclerotic Cardiovascular Disease ◽  
Oral Glucose Tolerance ◽  
Median Increase

Objective: Statin treatment reduces the risk of atherosclerotic cardiovascular disease but is associated with a modest increased risk of type 2 diabetes, especially in those with insulin resistance or prediabetes. Our objective was to determine the physiological mechanism for the increased type 2 diabetes risk. Approach and Results: We conducted an open-label clinical trial of atorvastatin 40 mg daily in adults without known atherosclerotic cardiovascular disease or type 2 diabetes at baseline. The co-primary outcomes were changes at 10 weeks versus baseline in insulin resistance as assessed by steady-state plasma glucose during the insulin suppression test and insulin secretion as assessed by insulin secretion rate area under the curve (ISR AUC ) during the graded-glucose infusion test. Secondary outcomes included glucose and insulin, both fasting and during oral glucose tolerance test. Of 75 participants who enrolled, 71 completed the study (median age 61 years, 37% women, 65% non-Hispanic White, median body mass index, 27.8 kg/m 2 ). Atorvastatin reduced LDL (low-density lipoprotein)-cholesterol (median decrease 53%, P <0.001) but did not change body weight. Compared with baseline, atorvastatin increased insulin resistance (steady-state plasma glucose) by a median of 8% ( P =0.01) and insulin secretion (ISR AUC ) by a median of 9% ( P <0.001). There were small increases in oral glucose tolerance test glucose AUC (median increase, 0.05%; P =0.03) and fasting insulin (median increase, 7%; P =0.01). Conclusions: In individuals without type 2 diabetes, high-intensity atorvastatin for 10 weeks increases insulin resistance and insulin secretion. Over time, the risk of new-onset diabetes with statin use may increase in individuals who become more insulin resistant but are unable to maintain compensatory increases in insulin secretion. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02437084.

Sign in / Sign up

Export Citation Format

Share Document